You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
長春高新(000661.SZ):子公司卡麥角林片臨牀試驗申請獲批

格隆匯8月11日丨長春高新(000661.SZ)公佈,近日,長春高新技術產業(集團)股份有限公司控股子公司——長春金賽藥業有限責任公司(簡稱“金賽藥業”)收到國家藥品監督管理局覈準簽發的《藥物臨牀試驗批準通知書》,金賽藥業卡麥角林片的境內生產藥品註冊臨牀試驗申請獲得批準。

卡麥角林片是金賽藥業開發的一款多巴胺受體激動劑,對多巴胺D2受體具有有效的激動劑活性,註冊分類爲化藥3類,擬開發用於高催乳素血癥/垂體催乳素腺瘤的治療。

目前治療高催乳素血癥、垂體催乳素腺瘤(無論微腺瘤或大腺瘤),首選多巴胺受體激動劑治療。卡麥角林是具有高度選擇性的多巴胺D2受體激動劑,是溴隱亭的換代藥物,抑制催乳素的作用更強大而不良反應相對減少,作用時間更長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account